Insights That Move the GPCR Field Forward

As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026.

Science used to reward the lone genius—the first author who “drove the project,” the PI whose name defined a field. But the problems we face today—metabolic disease, obesity, GPCR signaling complexity—are too layered, too multidimensional, too systemic for single-discipline solutions. As Hodson put it, the work he leads now would be impossible without partnerships. Whether it's human genetics, imaging platforms, peptide chemistry, or neural metabolic mapping—every piece re

When David Hodson’s lab teamed up with chemist Johannes Broichhagen aka JB (then a young researcher newly arrived during a home DIY moment), the goal was bold and elegant: Create a photo-switchable ligand to remotely control GPCR signaling with light. This was the moment when photopharmacology felt like the future. The literature was buzzing. Labs were competing. The idea was simple — turn signaling on or off with a flash of light.

A powerful new tool tracks GPCR internalization in native cells—no imaging, no overexpression. Learn how pH Sense changes the game for drug discovery.

October 2022 N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 receptor selectivity towards...